(P	E.O.
HOA	2 8 8004 E

TENT & IPAIN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449

DOCKET NO. 12475/49402 (formerly 12475/31)	SERIAL NO. 10/668,473
APPLICANT Jack B. JIANG et al.	
FILING DATE September 22, 2003	GROUP 1621 To Be Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,529,593*	July 16, 1985	Warrell, Jr. et al.	424	127	
	5,177,068*	January 5, 1993	Callingham et al.	514	184	
	5,258,376*	November 2, 1993	Bernstein	514	184	
	5,574,027*	November 12, 1996	Bernstein	514	184	
	5,747,482*	May 5, 1998	Bernstein	514	184	
	5,883,088*	March 16, 1999	Bernstein	514	184	
	5,968,922*	October 19, 1999	Bernstein	514	184	
	5,981,518*	November 9, 1999	Bernstein	514	184	
	5,998,397*	December 7, 1999	Bernstein	514	184	
	6,004,951*	December 21, 1999	Bernstein	514	184	
	6,048,851*	April 11, 2000	Bernstein	914	184	
	6,087,354*	July 11, 2000	Bernstein	514	184	
	6,656,615*	December 2, 2003	Dwilinski et al.	428	698	

^{*} A copy of the patent is not enclosed since the present application was filed after June 30, 2003.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	ION
						YES	NO

Sorfine Negani Genzales

4/13/06

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
d	Hart et al., "Antitumor Activity and Toxicity of Salts of Inorganic Group IIIa Metals: Aluminum, Gallium, Indium, and Thallium," Proc. Natl. Acad. Sci USA, Vol. 68, No. 7 (July 1971) pp. 1623-1626
b	D.J. Straus, "Gallium Nitrate in the Treatment of Lymphoma," Seminars in Oncology, Vol. 30, No. 2, Suppl. 5 (April 2003) pp. 25-33
	E.A. Van Leeuwen-Stok et al., "Cell Cycle Dependency of ⁶⁷ Gallium Uptake and Cytotoxicity in Human Cell Lines of Hematological Malignancies," Leukemia and Lymphoma, Vol 31(5-6) (November 1998) pp. 533-544
p	R.P. Warrell, Jr. et al., "Salvage Chemotherapy of Advanced Lymphoma with Investigational Drugs: Mitoguazone, Gallium Nitrate, and Etoposide 1,2," Cancer Treatment Response, Vol. 71, No. 1 (January 1987) pp. 47-51
Ja-	M.S. Myette et al., "Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells," Cancer Letters, Vol. 129, No. 2 (July 17, 1998) pp. 199-204
b	C.R. Chitambar et al., "Evaluation of Continuous-Infusion Gallium Nitrate and Hydroxyurea in Combination for the Treatment of Refractory Non-Hodgkin's Lymphoma," Am. J. Clin. Oncol., Vol. 20, No. 2 (April 1997) pp. 173-178
B	R.P. Warrell et al., "Gallium Nitrate Inhibits Calcium Resorption from Bone and is Effective Treatment for Cancer-related Hypercalcemia," J. Clin. Invest., Vol. 73 (May 1984) pp. 1487-1490
A	R.P. Warrell, Jr. et al., "Gallium Nitrate for Preservation of Bone Mass in Multiple Myeloma: Results of a Pilot Randomized Study," Journal of Bone and Mineral Research, Vol. 5 (Suppl. 2) (August 28, 1990) pp. S106
de la	R.P. Warrell, Jr. et al., "Low-Dose Gallium Nitrate for Prevention of Osteolysis in Myeloma: Results of a Pilot Randomized Study," Journal of Clinical Oncology, Vol. 11, No. 12 (December 1993) pp. 2443-2450
B	R.P. Warrell, Jr., "Gallium Nitrate for the Treatment of Bone Metastases," Cancer, Vol. 80, No. 8 (October 15, 1997) pp. 1680-1685
A	C.R. Chitambar, "Gallium Nitrate Revisited," Seminars in Oncology, Vol. 30, No. 2, Suppl. 5 (April 2003) pp. 1-4
	R.P. Warrell, Jr. et al., "Gallium Nitrate for Advanced Paget Disease of Bone: Effectiveness and Dose-REsponse Analysis," Annals of Internal Medicine, Vol. 113, No. 11 (December 1990) pp. 847-851
A	R. Bockman, "The Effects of Gallium Nitrate on Bone Resorption," Seminars in Oncology, Vol. 30, No. 2, Suppl.5 (April 2003) pp. 5-12
þ	N. Makkonen et al., "The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro," Inflamm. Res., Vol. 44, No. 12 (December 1995) pp. 523-528
1	G. Apseloff, "Therapeutic Uses of Gallium Nitrate: Past, Present, and Future," American Journal of Therapeutics, No. 6 (1999) pp. 327-339
1	I.M. Viktorova et al., "Gallium and Indium Acylates," pp. 929-930; translated from Doklady Akademii Nauk SSSR, Vol. 189, No. 3 (November 1969) pp. 541-42
do	H.C. Dudley et al., "Preparation and Properties of Gallium Lactate 1," The Journal of the American Chemical Society, Vol. 70 (September-December 1948) p. 3942-3943
	Per Artursson et al., "Caco-2-Monolayers in Experimental and Theoretical Predictions of Drug Transport," Advanced Drug Delivery Reviews, Vol. 46 (2001) pp. 27-43

Serfires Nazaris Sonzález

4/13/06

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
\$	Shiyin Yee, "In Vitro Permeability Acros Caco-2-Cells (Colonic) Can Predict in Vivo (Small Intestinal) Absorption in Man - Fact or Myth," Pharmaceutical Research, Vol. 14, No. 6 (1997) pp. 763-766
12	Edward Rudnic et al., "Oral Solid Dosage Forms," Chapter 92, Remington: The Science and Practice of Pharmacy, Vol. II, Alfonso R. Gennaro, Ed., 1995, pp. 1615-1649

N 1	1	
EXAMINER VILLE VILLE		DATE CONSIDERED
EXAMINER JOHNIO MASQUI	HB112ANI	DATE CONSIDERED 4/13/06
1-11	<i>P A</i> 1	'/
EXAMINER Initial if citation considered, y	hether of not oftation is in conform	nance with M.P.E.P. 609; draw line through
citation if not in conformance and not consider	lered. Include copy of this form wi	ith next communication to applicant.